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All cell types are capable of generating small heterogeneous vesicles, called extracellular 
vesicles (EVs). EVs are released from activated or stressed parent cells into the extracellular 
space such as plasma, cerebrovascular fluid, breast milk, urine, and saliva and reflect the 
activation status and phenotype of the parent cell from which they were derived1. Based on 
biogenesis, content and size, EVs are classified as exosomes (40 to 100 nm), microparticles 
(also termed microvesicles) (100-1000 nm) and apoptotic bodies (1-5 µm)2. Extracellular 
vesicles were initially identified as cellular “dust” and considered to be “cell debris”. 
However there is now good evidence in experimental and clinical studies demonstrating that 
EVs are biomarkers of disease including cancer, metabolic disorders and cardiovascular 
diseases3, 4. Moreover it has become increasingly apparent that they are biologically active 
and are important signalling vehicles and regulators of local and distant cell-cell 
communication1. EVs act as biovectors carrying cargo such as proteins, lipids, receptors, 
RNA, microRNA (miR) and enzymes, which are derived primarily from parent cells. They 
communicate with target cells, through diverse mechanisms, including release of cargo into 
the extracellular space, cell membrane binding, cell membrane fusion and endocytosis by 
target cells. Through these interactions and transfer of cargo, EVs influence the function of 
other cells2. For example, neutrophil-derived microvesicles carry cytokines, which function 
as pro-inflammatory mediators1. Cancer cell-derived microparticles release metalloproteases 
and promote tumor invasion and metastases and platelet-derived microparticles transfer miR-
142 into endothelial cells causing endothelial dysfunction3, 5 .   
As biomarkers in cardiovascular disease, platelet microparticles correlate with the 
development of hypertension, levels of endothelial cell-derived microparticles associate with 
type 2 diabetes and hypertension and circulating exosomes associate with myocardial 
infarction, cardiomyopathies and pulmonary hypertension5. In hypertension, EV levels also 
correlate with arterial stiffness, endothelial dysfunction and impaired vasoreactivity and 
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accordingly have been suggested to reflect underlying vascular status. Beyond their role as 
vascular biomarkers, EVs directly regulate endothelial and vascular smooth muscle cell 
function by influencing production of nitric oxide and reactive oxygen species, pro-
inflammatory signaling, apoptosis and senescence2, 6. These processes have been implicated 
in various experimental models of hypertension, including Ang II-infused, SHRSP, DOCA-
salt, SHR and in patients with essential hypertension.  
In the current issue of the journal, Monticone et al7 advance the field by 
demonstrating that the number of EVs derived mainly from leucocytes and endothelial cells 
is significantly increased in patients with primary aldosteronism when compared to 
individuals with essential hypertension and those with normal blood pressure, effects that 
were normalized post-adrenelectomy. Moreover, findings from this study showed a strong 
correlation between serum aldosterone levels and number of circulating EVs. Similar findings 
have been observed in experimental models of aldosterone-salt-induced hypertension (8). 
Patients with primary aldosteronism have a higher prevalence of target organ damage and 
cardiovascular events compared to patients with essential hypertension and endothelial 
dysfunction is associated, at least partially, with the increased cardiovascular risk observed in 
these patients9, 10. Therefore, considering EVs as surrogate markers of endothelial dysfunction 
and vascular injury, these data support the notion that the greater the magnitude of 
endothelial dysfunction in primary aldosteronism the higher the levels of circulating EVs. 
Renal-derived urinary exosomes have also been shown to be increased in patients with 
hyperaldosteronism and have been suggested to be markers of aldosterone-induced renal 
disease11-13.  
Despite the accumulating evidence showing a relationship between 
hyperaldosteronism and EV formation, it remains unclear whether increased production is a 
primary effect of high levels of aldosterone or whether increased generation is secondary to 
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aldosterone-induced vascular injury and hypertension. Also, it may be possible that changes 
in plasma K+ due to hyperaldosteronism influence EV production, as previously suggested12. 
Shear stress and elevated blood pressure probably contribute, at least in part to increased 
circulating EVs, but it may be possible that aldosterone itself can stimulate generation of EVs 
from various cell types. We previously demonstrated that generation of endothelial cell-
derived microparticles depends on mechanisms involving Rho kinase, cholesterol-rich 
microdomains and cytoskeletal organization2, processes that are influenced by aldosterone 
signalling through mineralocorticoid receptors14. Hence, it may be possible that in primary 
aldosteronism, aldosterone itself directly induces production of EVs. 
Monticone et al further characterised EVs in primary aldosteronism and demonstrated 
that mRNA expression of caspase-1 (CASP1) and pre-pro-ET-1 (EDN1) is increased7. These 
vesicles were functionally active, since they promoted endothelial apoptosis and reduced 
angiogenesis in in vitro studies, indicating that they could themselves be involved in vascular 
dysfunction in primary aldosteronism. Previous studies showed that microparticles stimulate 
endothelial ROS formation and inflammatory responses via the endothelin-1 (ET-1) system 
and hence may be a molecular mechanism underlying EV-associated vascular damage in 
hyperaldosteronism. However, Monticone et al failed to demonstrate any effect of bosentan, a 
non-selective antagonist of ETA and ETB receptors, and a caspase-1 inhibitor, on EVs-
stimulated endothelial cell angiogenesis and apoptosis7. Therefore, it is likely that CASP1- 
and EDN1-loaded EVs induce vascular dysfunction through pathways independent of caspase 
and ETAR/ETBR (Figure 1). Considering the wide array of cargo carried, it is likely that 
many factors influence EV-induced endothelial dysfunction in primary aldosteronism. 
The present study adds to the concept that EVs are biomarkers of endothelial 
dysfunction in hypertension and that excess aldosterone amplifies this process. The findings 
also support previous studies showing that EVs influence intercellular communication by 
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regulating endothelial cell apoptosis and angiogenesis. However, there are a number of 
unanswered questions and limitations of the study that warrant further consideration. Firstly, 
it still remains unclear whether aldosterone itself or vascular dysfunction secondary to 
hyperaldosteronism causes the increase in circulating endothelial EVs. Secondly, reasons 
why leukocyte-derived EVs are increased in patients with primary aldosteronism were not 
explored. Thirdly, the significance of increased expression of CASP and EDN1 specifically 
in EVs from patients with primary aldosteronism is unclear. Finally, there is no attempt to 
examine how EVs from primary aldosteronism patients interact with target endothelial cells. 
Nevertheless, some new concepts of clinical relevance are suggested by Monticone et al7, 
specifically that CASP- and EDN1- containing EVs may be putative biomarkers of 
hyperaldosteronism. Further large clinical studies are needed for confirmation.  
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Figure legend 
Figure 1. Potential mechanisms linking primary aldosteronism (PA) and extracellular 
vesicle (EV) formation, and how they may impair vascular homeostasis, leading to 
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cardiovascular disease. Hyperaldosteronism promotes increased generation of EDN1 and 
CASP1-containing EVs. High levels of aldosterone may influence EV production through 
direct and indirect mechanisms. Once formed, EVs interact with target vascular cells and 
induce activation of signalling pathways that influence endothelial/vascular function. 
Amplification of this process in primary aldosteronism may contribute to endothelial/vascular 
injury, which contributes to target organ damage and increased cardiovascular risk.  
 
 
 
